alemtuzumab
Selected indexed studies
- Alemtuzumab for haematological malignancies. (Ann Hematol, 2025) [PMID:40214729]
- Alemtuzumab. (Drugs, 2003) [PMID:12790693]
- Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis. (Drugs, 2021) [PMID:33367970]
_Worker-drafted node — pending editorial review._
Connections
alemtuzumab is a side effect of
Sources
- Alemtuzumab for haematological malignancies. (2025) pubmed
- Alemtuzumab. (2003) pubmed
- Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis. (2021) pubmed
- Alemtuzumab for the treatment of multiple sclerosis. (2018) pubmed
- Alemtuzumab as Treatment for Multiple Sclerosis. (2018) pubmed
- Alemtuzumab for Multiple Sclerosis. (2016) pubmed
- Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. (2024) pubmed
- Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom. (2022) pubmed
- [Alemtuzumab therapy 2017]. (2017) pubmed
- Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review. (2025) pubmed